/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers
S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

OncLive® On Air · Oct 14, 2026

B7-H4 ADCs show >60% response rates in gynecologic cancers by reprogramming the tumor immune microenvironment, driving phase 3 trials.

B7-H4 ADCs Counteract Tumor Immunosuppression to Sensitize Cold Gynecologic Tumors to Checkpoint Inhibitors

Dr. Alvarez-Secord explains that unlike FR-alpha or HER2 ADCs that target growth signals, B7-H4 is embedded in immune regulation. Administering a B7-H4 ADC relieves microenvironment immunosuppression while tumor cell kill releases neoantigens, creating synergy when paired with checkpoint inhibitors like dostarlimab.

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers thumbnail

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

OncLive® On Air·a month ago

Adding Aprepitant and Upfront Growth Factors Preserves Dosing Intensity with Topo-1 ADCs

Proactive management of topoisomerase-1 ADC payload toxicities requires upgrading antiemetic regimens by adding neurokinin-1 inhibitors such as aprepitant to standard ondansetron and dexamethasone. Dr. Alvarez-Secord also utilizes upfront growth factor support for at-risk patients and prompt anti-motility treatment to prevent dose interruptions.

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers thumbnail

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

OncLive® On Air·a month ago

Switching Payloads Restores ADC Antitumor Efficacy Even When Re-Targeting the Same Surface Protein

Clinical experience demonstrates that patients progressing on targeted agents can still respond to ADCs directed against the identical target if the mechanism or payload is switched. However, phase 3 clinical trial exclusions for prior topoisomerase-1 ADC exposure currently restrict the generation of sequencing data.

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers thumbnail

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

OncLive® On Air·a month ago

PuxiSAM Reaches 60% Response Rates in Post-IO Relapsed Endometrial Cancer

Patients whose endometrial cancer progresses after frontline platinum-based chemotherapy and checkpoint inhibition face a major treatment gap. Data from the Blue Star study showed the ADC PuxiSAM achieved confirmed overall response rates above 60% across cohorts, specifically including this previously treated post-IO population.

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers thumbnail

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

OncLive® On Air·a month ago

High B7-H4 Prevalence in Gynecologic Cancers May Eliminate Stringent Biomarker Threshold Requirements

Unlike targets like FR-alpha and HER2 that require high expression thresholds to yield significant clinical responses, B7-H4 exhibits expression rates between 80% and 90% across ovarian and endometrial cancers. This pervasive prevalence may allow broader patient eligibility without requiring restrictive biomarker cutoffs.

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers thumbnail

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

OncLive® On Air·a month ago